Last updated: 15 February 2023 at 5:54pm EST

Albert Robichaud Net Worth




The estimated Net Worth of Albert Robichaud is at least $19.9 Milión dollars as of 9 December 2019. Albert Robichaud owns over 25,000 units of Sage Therapeutics Inc stock worth over $1,021,636 and over the last 10 years he sold SAGE stock worth over $15,170,200. In addition, he makes $3,667,260 as Chief Scientific Officer at Sage Therapeutics Inc.

Albert Robichaud SAGE stock SEC Form 4 insiders trading

Albert has made over 10 trades of the Sage Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 25,000 units of SAGE stock worth $1,604,000 on 9 December 2019.

The largest trade he's ever made was selling 60,000 units of Sage Therapeutics Inc stock on 14 December 2017 worth over $9,565,800. On average, Albert trades about 7,510 units every 70 days since 2014. As of 9 December 2019 he still owns at least 136,400 units of Sage Therapeutics Inc stock.

You can see the complete history of Albert Robichaud stock trades at the bottom of the page.





Albert Robichaud biography

Dr. Albert J. Robichaud Ph.D. serves as Chief Scientific Officer of the Company. From 2010 to 2011, he was Vice President of Chemistry and Pharmacokinetic Sciences at Lundbeck, Inc., where he was responsible for the drug discovery, analytical, computational and pharmacokinetics departments focused on synaptic transmission and neuroinflammation. From 2002 to 2010, Dr. Robichaud was Senior Director and Head of the Neuroscience Discovery Chemistry department of Wyeth Research. During his tenure there, his group successfully delivered more than 15 drug candidates into clinical development in a broad range of neuroscience indications. Dr. Robichaud has co-authored more than 135 manuscripts and abstracts, and is a co-inventor on 70 patents and patent applications. Dr. Robichaud earned a B.S. in chemistry from Rensselaer Polytechnic Institute, a Ph.D. in organic chemistry from the University of California, Irvine and was an American Chemical Society postdoctoral fellow at Colorado State University.

What is the salary of Albert Robichaud?

As the Chief Scientific Officer of Sage Therapeutics Inc, the total compensation of Albert Robichaud at Sage Therapeutics Inc is $3,667,260. There are 5 executives at Sage Therapeutics Inc getting paid more, with Jeffrey Jonas having the highest compensation of $9,902,080.



How old is Albert Robichaud?

Albert Robichaud is 59, he's been the Chief Scientific Officer of Sage Therapeutics Inc since 2011. There are 4 older and 10 younger executives at Sage Therapeutics Inc. The oldest executive at Sage Therapeutics Inc is Dr. Jeffrey M. Jonas, 68, who is the Chief Innovation Officer, Chair of the Science & Technology Forum and Director.

What's Albert Robichaud's mailing address?

Albert's mailing address filed with the SEC is C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE, MA, 02142.

Insiders trading at Sage Therapeutics Inc

Over the last 10 years, insiders at Sage Therapeutics Inc have traded over $190,046,458 worth of Sage Therapeutics Inc stock and bought 150,092 units worth $6,260,297 . The most active insiders traders include Kevin P Starr, Robert Nelsen a Michael F Cola. On average, Sage Therapeutics Inc executives and independent directors trade stock every 32 days with the average trade being worth of $256,667. The most recent stock trade was executed by Kimi Iguchi on 2 January 2024, trading 1,642 units of SAGE stock currently worth $2,233.



What does Sage Therapeutics Inc do?

sage therapeutics is a neuroscience-focused company developing medicines to treat life-threatening, rare cns disorders. our mission is to make life better for patients with central nervous systems diseases by discovering, developing, and delivering important new medicines to the market. to achieve that mission we leverage compelling science, a robust clinical foundation, strong partnerships, and a world-class team of founders, advisors, investors, scientists and managers. sage’s lead program, sage-547, is in clinical development for super-refractory status epilepticus (srse) and is the first of many compounds the company is developing in its portfolio of potential seizure medicines. sage’s robust chemistry platform has generated multiple new compounds that target the gabaa and nmda receptors, which have demonstrated preclinical activity. sage therapeutics is a private company launched in 2010 by an experienced team of r&d leaders, cns experts and investors.



What does Sage Therapeutics Inc's logo look like?

Sage Therapeutics Inc logo

Complete history of Albert Robichaud stock trades at Sage Therapeutics Inc

Dátum
#
Spoločnosť
Človek
Trans.
Transakcia
Počet akcií Cena za akciu Celková cena Počet akcií po Zdroj
9 Dec 2019 Albert Robichaud
Chief Scientific Officer
Kúpa 25,000 $64.16 $1,604,000
9 Dec 2019
136,400
14 Dec 2017 Albert Robichaud
Chief Scientific Officer
Predaj 60,000 $159.43 $9,565,800
14 Dec 2017
94,259
28 Oct 2016 Albert Robichaud
Chief Scientific Officer
Využitie opcie 15,287 $1.36 $20,790
28 Oct 2016
155,509
12 Jul 2016 Albert Robichaud
Chief Scientific Officer
Predaj 22,000 $40.00 $880,000
12 Jul 2016
140,222
25 Jan 2016 Albert Robichaud
Chief Scientific Officer
Predaj 20,000 $40.02 $800,400
25 Jan 2016
162,222
25 Jan 2016 Albert Robichaud
Chief Scientific Officer
Predaj 20,000 $40.02 $800,400
25 Jan 2016
162,222
3 Aug 2015 Albert Robichaud
Chief Scientific Officer
Predaj 12,000 $67.06 $804,720
3 Aug 2015
182,222
1 Jul 2015 Albert Robichaud
Chief Scientific Officer
Predaj 16,000 $72.13 $1,154,080
1 Jul 2015
194,222
1 Jun 2015 Albert Robichaud
Chief Scientific Officer
Predaj 16,000 $72.80 $1,164,800
1 Jun 2015
210,222
23 Jul 2014 Albert Robichaud
Chief Scientific Officer
Kúpa 4,000 $18.00 $72,000
23 Jul 2014
226,222


Sage Therapeutics Inc executives and stock owners

Sage Therapeutics Inc executives and other stock owners filed with the SEC include: